In case you’re still getting your act together early in 2023, let me help make sense of what’s been shaking with Virtus Junxit.
Two recent alerts made some astonishing moves early this year and it’s must know material.
Brought to your attention most recently on 12/12/22, (ALBT) hit the ground running in the new year.
From 12/12’s open on $.32, ALBT has now rocketed an approximate 89% to 1/3/23’s $.6051 high.
For roughly 3 weeks, ALBT delivered a brain-busting move. But NBY one-upped it.
Delivered on 12/30/22, NBY opened that day at $1.37 and made a strong intraday surge.
But it wasn’t done there…
On 1/4/23, NBY nailed a high of $2.66 for an approximate short term surge of 94%.
Two alerts. Approximately 183% in combined breakout runs.
Listen. We could sit around and pat ourselves on the back all day long, but that isn’t going to get us anywhere.
Instead, I’ve been hard at work putting together this must-see report.
Based on this profile’s low float (under 2Mn shares), a long list of granted patents (+ patent applications), a recent uplisting to the Nasdaq Capital Market, and January news regarding huge steps forward in a potential obesity treatment, this Nasdaq profile requires immediate attention.
Pull up *Clearmind Medicine Inc. (CMND)* right now.
Clearmind is a psych-e-delic pharmaceutical biotech company focused on the discovery and development of novel psych-e-delic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psych-e-delic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
Discover How Clearmind Medicine Inc. Is Developing Innovative Psych-e-delic-Based Medicines For Treating Addiction & Mental Health.
Clearmind Medicine Inc.’s primary objective is to research and develop psych-e-delic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of seven patent families.
Clearmind Medicine Inc. intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Clearmind’s flagship treatments are focused on Alcohol Use Disorder (AUD), which is incredibly common. It varies from mild to excessive, and describes a person’s inability to restrict their alcohol consumption, despite negative social, occupational, or health consequences.
Alcohol Use Disorder (AUD) encompasses conditions that are referred to as alcohol abuse, alcohol dependence, alcohol addiction, and alcoholism. (1)
AUD is a medical condition characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences.
Considered a brain disorder AUD can be mild, moderate, or severe.
The good news is that no matter how severe the problem may seem, evidence-based treatment with behavioral therapies, mutual-support groups, and/or medications can help people with AUD achieve and maintain recovery.(2)
According to a national survey, 14.1 million adults ages 18 and older (5.6% of this age group) had AUD in 2019.
Among youth, an estimated 414,000 adolescents ages 12–17 (1.7% of this age group) had AUD during this timeframe.
What increases the risk for AUD? A person’s risk for developing AUD depends, in part, on how much, how often, and how quickly they consume alcohol.
Alcohol misuse, which includes binge drinking and heavy alcohol use, over time increases the risk of AUD.
Other factors also increase the risk of AUD, such as:
Drinking at an early age. A recent national survey found that among people ages 26 and older, those who began drinking before age 15 were more than 5 times as likely to report having AUD in the past year as those who waited until age 21 or later to begin drinking. The risk for females in this group is higher than that of males.
Genetics and family history of alcohol problems. Genetics play a role, with heritability approximately 60 percent; however, like other chronic health conditions, AUD risk is influenced by the interplay between a person’s genes and their environment. Parents’ drinking patterns may also influence the likelihood that a child will one day develop AUD.
Mental health conditions and a history of trauma. A wide range of psychiatric conditions—including depression, post-traumatic stress disorder, and attention deficit hyperactivity disorder—are comorbid with AUD and are associated with an increased risk of AUD. People with a history of childhood trauma are also vulnerable to AUD.
Breaking the Cycle
Clearmind Medicine Inc. believes that MEAI breaks the vicious binge-drinking cycle at the decision point to drink more alcohol,by potentially innervating neural pathways such as 5-HT1A that lead to “sensible behavior.”
Anecdotal reports and pre-clinical in-vivo results indicate on the self-limiting property of MEAI—unlike traditional treatments.
The literature shows that 5-HT1A receptors are associated with controlling craving behavior across the board. This indicates that MEAI may have a wide range of applications beyond binge drinking.
Grab more key details from the company presentation.
Now to the pressing details…
CMND has a tiny float.
Like, real small.
According to Yahoo Finance, CMND has a float in the neighborhood of 1.17Mn shares.
Why is this important? Simple. When a profile has this few shares available, the potential for volatility needs to be noted.
And noted on a daily basis. If a potential catalyst like a positive news comes out on a profile with such few shares, the volatility can be enough to make your head spin.
But that’s not all. CMND has a spate of granted patents with multiple more applications awaiting approval.
CMND’s IP portfolio has 23 patent filings:
- Consists of 7 utility patent families owned by the company.
- Claims include method of use and composition of matter.
- The 7 patent families include 8 granted patents and 15 pending applications.
Huge January news? Yes, CMND has that too.
Here’s their huge announcement:
Israel-Based Clearmind Medicine Shows Efficacy of Psych-e-delic- Derived Obesity Treatment in Pre-Clinical Trial
In a series of pre-clinical trials, Clearmind’s drug candidate MEAI significantly reduced body weight, improved fatty liver disease, and normalized insulin sensitivity
Tel Aviv, Israel / Vancouver, Canada, Jan. 05, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “Company”), a biotech company focused on discovery and development of novel psych-e-delic-derived therapeutics to solve major undertreated health problems, today announced positive pre-clinical results demonstrating efficacy of its drug candidate MEAI for treating obesity and metabolic syndrome.
The study, conducted at the Hebrew University of Jerusalem, as part of a collaboration established with the university’s technology transfer company, Yissum, included multi-parameter metabolic assessments such as body weight, fat mass, glucose tolerance, insulin sensitivity, liver enzymes and fat accumulation as well as food consumption patterns. It included three groups of rodents: one was fed a standard diet, another a high-fat diet, and the third a high-fat diet group along with treatment with MEAI.
The animals treated with MEAI showed increased energy expenditure, better fat utilization and weight loss of 20%, while reducing their overall fat mass and preserving their lean body mass. No effect on motivation and well-being was observed. Additionally, MEAI treatment yielded normalization of insulin levels, improved glucose tolerance as well as reduced fat and triglycerides accumulation in the liver. These results were significantly better than those obtained in the high fat, untreated group.
Furthermore, a significant reduction in sucrose preference was observed following administration of MEAI for two days at the effective dose, supporting the notion that it can dampen the hedonic value of rewarding stimuli. Thus, MEAI may be beneficial for the treatment of compulsive reward-seeking behavior or excessive consumption of sweet foods.
“We’re very excited about these results, which suggest that MEAI may be effective in treating obesity, one of the world’s most pressing problems,” said Dr. Adi Zuloff-Shani, Clearmind’s Chief Executive Officer. “These additional positive results in our treatment of addictions, once again indicate MEAI’s potential to become a viable treatment for a variety of disorders.”
Dr. Adi Zuloff-Shani also noted that the global market for obesity drugs was valued by third-party sources in 2021 at $1.9Bn.
The study was led by Prof. Joseph Tam, D.M.D., Ph.D., head of the Obesity and Metabolism Laboratory and Associate Professor of Pharmacology at the Hebrew University’s Institute for Drug Research and Dr. Saja Baraghithy, Ph.D.
“While there is some evidence suggesting that psych-e-delic drugs, such as L-S-D and psi-lo-cybin, may be effective in treating obesity and other eating disorders, no solid experimental proof really exists, until now. We show for the first time that MEAI’s obesity effect works by altering various metabolic processes in the body, such as energy expenditure, fat storage and glucose utilization to promote weight loss,” said Prof. Tam. “These findings suggest that MEAI may be beneficial for reducing the risk of obesity-related complications, such as type 2 diabetes and fatty liver diseases.”
Like I said, huge news.
But nothing may be bigger than what CMND accomplished just a few months back:
Hot off a recent IPO and uplisting to the Nasdaq Capital Market, exposure is the name of the game.
As Clearmind Medicine Inc. continues to get their name out there through this uplisting and notoriety that comes from being added to the Nasdaq, CMND could gain major traction early in 2023 and beyond.
You’re officially on the clock. For Monday’s opening bell, get Clearmind Medicine Inc. (CMND) on your radar.
DISCLAIMER: We have not been compensated for our profile on (NBY). We own zero shares of (NBY). We anticipate to potentially provide marketing for (NBY) at a future date. If that occurs, we will disclose compensation accordingly.